Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Community
/
India
/
Pharmaceuticals & Biotech
/
Indegene
INDGN
Indegene
Digital Transformation And AI Adoption Will Expand Pharma Market
AN
AnalystConsensusTarget
Not Invested
Consensus Narrative from 6 Analysts
Published
11 May 25
Updated
15 Aug 25
7
Set Fair Value
0
votes
Share
AnalystConsensusTarget
's Fair Value
₹644.67
10.1% undervalued
intrinsic discount
15 Aug
₹579.40
Loading
1Y
-1.9%
7D
1.3%
Author's Valuation
₹644.7
10.1% undervalued
intrinsic discount
AnalystConsensusTarget Fair Value
View Valuation
Narrative
Updates
0
Valuator
Company Info
Notes
AnalystConsensusTarget Fair Value
₹644.7
10.1% undervalued
intrinsic discount
Future estimation in
3 Years
time period
Past
Future
0
41b
2020
2021
2022
2023
2024
2025
2026
2027
2028
Revenue ₹41.1b
Earnings ₹6.5b
Revenue
Profit Margin
Future PE
Revenue
% p.a.
0
Decrease
Increase
Current revenue growth rate
11.73%
Life Sciences revenue growth rate
0.32%
Other Inputs & Calculation
Risk Level (Discount Rate)
Our default considers factors like the company's size, volatility, profitablity and country of operation.
Risk Level (Discount Rate)
%
0
Decrease
Increase
Current discount rate
13.32%
Calculation
₹6.48b
Earnings '28
x
38.53x
PE Ratio '28
=
₹249.59b
Market Cap '28
₹249.59b
Market Cap '28
/
265.57m
No. shares '28
=
₹939.82
Share Price '28
₹939.82
Share Price '28
Discounted to 2025 @ 13.33% p.a.
=
₹645.70
Fair Value '25